NU-CIPROFLOX 0.3 %
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE) : 0.3 % · DIN 02333228 · NU-PHARM INC
Health Canada status: CANCELLED (UNRETURNED ANNUAL)
What is NU-CIPROFLOX?
NU-CIPROFLOX 0.3 % contains CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE) : 0.3 %. It is listed in the Health Canada Drug Product Database under DIN 02333228, held by NU-PHARM INC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 28-Mar-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02333228 |
|---|---|
| Brand name | NU-CIPROFLOX |
| Generic / active ingredient | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE) : 0.3 % |
| Manufacturer | NU-PHARM INC |
| Strength | 0.3 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01AE03 CIPROFLOXACIN |
| Biosimilar | No |
| Health Canada status | CANCELLED (UNRETURNED ANNUAL) |
| Status date | 28-Mar-2018 |
Is CIPROFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01AE03 CIPROFLOXACIN. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CILOXAN | 0.3 % | OINTMENT | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02200864 |
| SANDOZ CIPROFLOXACIN | 0.3 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02387131 |
| APO-CIPROFLOX | 0.3 % | SOLUTION | APOTEX INC | DORMANT | DIN 02263130 |
| PMS-CIPROFLOXACIN 0.3% | 0.3 % | SOLUTION | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02253933 |
Who else supplies CIPROFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CIPROFLOXACIN appears in 449 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.